nodes	percent_of_prediction	percent_of_DWPC	metapath
Bosentan—Restless legs syndrome—Varenicline—nicotine dependence	0.0455	0.0539	CcSEcCtD
Bosentan—Peripheral ischaemia—Varenicline—nicotine dependence	0.0357	0.0423	CcSEcCtD
Bosentan—Libido increased—Varenicline—nicotine dependence	0.0214	0.0253	CcSEcCtD
Bosentan—Toothache—Varenicline—nicotine dependence	0.0214	0.0253	CcSEcCtD
Bosentan—Intestinal obstruction—Varenicline—nicotine dependence	0.0191	0.0226	CcSEcCtD
Bosentan—Eye irritation—Varenicline—nicotine dependence	0.0152	0.0181	CcSEcCtD
Bosentan—Disturbance in attention—Varenicline—nicotine dependence	0.015	0.0178	CcSEcCtD
Bosentan—Gastrooesophageal reflux disease—Varenicline—nicotine dependence	0.0144	0.0171	CcSEcCtD
Bosentan—Musculoskeletal pain—Varenicline—nicotine dependence	0.0132	0.0156	CcSEcCtD
Bosentan—Influenza like illness—Varenicline—nicotine dependence	0.0126	0.015	CcSEcCtD
Bosentan—Nightmare—Varenicline—nicotine dependence	0.0126	0.0149	CcSEcCtD
Bosentan—Photophobia—Varenicline—nicotine dependence	0.0122	0.0145	CcSEcCtD
Bosentan—CYP2C9—CYP2E1 reactions—CYP2A7—nicotine dependence	0.0118	0.0756	CbGpPWpGaD
Bosentan—Mouth ulceration—Varenicline—nicotine dependence	0.0118	0.0139	CcSEcCtD
Bosentan—EDNRB—Peptide GPCRs—OPRM1—nicotine dependence	0.0109	0.0699	CbGpPWpGaD
Bosentan—Eczema—Varenicline—nicotine dependence	0.0105	0.0125	CcSEcCtD
Bosentan—Atrial fibrillation—Varenicline—nicotine dependence	0.00997	0.0118	CcSEcCtD
Bosentan—Thirst—Varenicline—nicotine dependence	0.00993	0.0118	CcSEcCtD
Bosentan—Hypoglycaemia—Varenicline—nicotine dependence	0.00968	0.0115	CcSEcCtD
Bosentan—Lethargy—Varenicline—nicotine dependence	0.00964	0.0114	CcSEcCtD
Bosentan—Cerebrovascular accident—Varenicline—nicotine dependence	0.00964	0.0114	CcSEcCtD
Bosentan—Disturbance in sexual arousal—Varenicline—nicotine dependence	0.00937	0.0111	CcSEcCtD
Bosentan—Affect lability—Varenicline—nicotine dependence	0.0093	0.011	CcSEcCtD
Bosentan—Irritability—Varenicline—nicotine dependence	0.00902	0.0107	CcSEcCtD
Bosentan—Mood swings—Varenicline—nicotine dependence	0.00895	0.0106	CcSEcCtD
Bosentan—Liver function test abnormal—Varenicline—nicotine dependence	0.00872	0.0103	CcSEcCtD
Bosentan—Dry skin—Varenicline—nicotine dependence	0.00866	0.0103	CcSEcCtD
Bosentan—Abdominal pain upper—Varenicline—nicotine dependence	0.00863	0.0102	CcSEcCtD
Bosentan—Hypokalaemia—Varenicline—nicotine dependence	0.0086	0.0102	CcSEcCtD
Bosentan—Cramp muscle—Varenicline—nicotine dependence	0.00851	0.0101	CcSEcCtD
Bosentan—Nasopharyngitis—Varenicline—nicotine dependence	0.00845	0.01	CcSEcCtD
Bosentan—Abdominal distension—Varenicline—nicotine dependence	0.00822	0.00974	CcSEcCtD
Bosentan—Asthma—Varenicline—nicotine dependence	0.00817	0.00967	CcSEcCtD
Bosentan—Angina pectoris—Varenicline—nicotine dependence	0.00795	0.00942	CcSEcCtD
Bosentan—Bronchitis—Varenicline—nicotine dependence	0.00785	0.0093	CcSEcCtD
Bosentan—EDNRA—Peptide GPCRs—OPRM1—nicotine dependence	0.0078	0.05	CbGpPWpGaD
Bosentan—Pollakiuria—Varenicline—nicotine dependence	0.00754	0.00894	CcSEcCtD
Bosentan—Weight increased—Varenicline—nicotine dependence	0.00743	0.0088	CcSEcCtD
Bosentan—Hyperglycaemia—Varenicline—nicotine dependence	0.00737	0.00873	CcSEcCtD
Bosentan—CYP2C9—Xenobiotics—CYP2A7—nicotine dependence	0.0073	0.0469	CbGpPWpGaD
Bosentan—Infestation NOS—Varenicline—nicotine dependence	0.00728	0.00862	CcSEcCtD
Bosentan—Infestation—Varenicline—nicotine dependence	0.00728	0.00862	CcSEcCtD
Bosentan—Stevens-Johnson syndrome—Varenicline—nicotine dependence	0.00722	0.00855	CcSEcCtD
Bosentan—Acute coronary syndrome—Varenicline—nicotine dependence	0.00718	0.0085	CcSEcCtD
Bosentan—Myocardial infarction—Varenicline—nicotine dependence	0.00714	0.00845	CcSEcCtD
Bosentan—Stomatitis—Varenicline—nicotine dependence	0.0071	0.00841	CcSEcCtD
Bosentan—Conjunctivitis—Varenicline—nicotine dependence	0.00708	0.00838	CcSEcCtD
Bosentan—Hepatobiliary disease—Varenicline—nicotine dependence	0.00689	0.00816	CcSEcCtD
Bosentan—Epistaxis—Varenicline—nicotine dependence	0.00687	0.00813	CcSEcCtD
Bosentan—Sinusitis—Varenicline—nicotine dependence	0.00683	0.00809	CcSEcCtD
Bosentan—Bradycardia—Varenicline—nicotine dependence	0.00665	0.00788	CcSEcCtD
Bosentan—Hypoaesthesia—Varenicline—nicotine dependence	0.0065	0.0077	CcSEcCtD
Bosentan—Urinary tract disorder—Varenicline—nicotine dependence	0.00645	0.00765	CcSEcCtD
Bosentan—Oedema peripheral—Varenicline—nicotine dependence	0.00644	0.00763	CcSEcCtD
Bosentan—Urethral disorder—Varenicline—nicotine dependence	0.00641	0.00759	CcSEcCtD
Bosentan—EDNRB—GPCR ligand binding—TAS2R16—nicotine dependence	0.00621	0.0398	CbGpPWpGaD
Bosentan—Erythema multiforme—Varenicline—nicotine dependence	0.00618	0.00732	CcSEcCtD
Bosentan—Eye disorder—Varenicline—nicotine dependence	0.00611	0.00724	CcSEcCtD
Bosentan—Tinnitus—Varenicline—nicotine dependence	0.00609	0.00722	CcSEcCtD
Bosentan—Cardiac disorder—Varenicline—nicotine dependence	0.00607	0.00719	CcSEcCtD
Bosentan—Angiopathy—Varenicline—nicotine dependence	0.00593	0.00702	CcSEcCtD
Bosentan—Immune system disorder—Varenicline—nicotine dependence	0.0059	0.00699	CcSEcCtD
Bosentan—Mediastinal disorder—Varenicline—nicotine dependence	0.00589	0.00698	CcSEcCtD
Bosentan—Chills—Varenicline—nicotine dependence	0.00586	0.00695	CcSEcCtD
Bosentan—Mental disorder—Varenicline—nicotine dependence	0.00573	0.00678	CcSEcCtD
Bosentan—Malnutrition—Varenicline—nicotine dependence	0.00569	0.00674	CcSEcCtD
Bosentan—Erythema—Varenicline—nicotine dependence	0.00569	0.00674	CcSEcCtD
Bosentan—Flatulence—Varenicline—nicotine dependence	0.00561	0.00664	CcSEcCtD
Bosentan—Back pain—Varenicline—nicotine dependence	0.0055	0.00652	CcSEcCtD
Bosentan—Muscle spasms—Varenicline—nicotine dependence	0.00547	0.00648	CcSEcCtD
Bosentan—Vision blurred—Varenicline—nicotine dependence	0.00536	0.00635	CcSEcCtD
Bosentan—Tremor—Varenicline—nicotine dependence	0.00533	0.00631	CcSEcCtD
Bosentan—Anaemia—Varenicline—nicotine dependence	0.00526	0.00623	CcSEcCtD
Bosentan—Angioedema—Varenicline—nicotine dependence	0.0052	0.00616	CcSEcCtD
Bosentan—EDNRB—Peptide ligand-binding receptors—OPRM1—nicotine dependence	0.00512	0.0329	CbGpPWpGaD
Bosentan—Vertigo—Varenicline—nicotine dependence	0.00511	0.00606	CcSEcCtD
Bosentan—Syncope—Varenicline—nicotine dependence	0.0051	0.00604	CcSEcCtD
Bosentan—Palpitations—Varenicline—nicotine dependence	0.00503	0.00596	CcSEcCtD
Bosentan—Loss of consciousness—Varenicline—nicotine dependence	0.005	0.00592	CcSEcCtD
Bosentan—Cough—Varenicline—nicotine dependence	0.00496	0.00588	CcSEcCtD
Bosentan—Chest pain—Varenicline—nicotine dependence	0.00484	0.00574	CcSEcCtD
Bosentan—Arthralgia—Varenicline—nicotine dependence	0.00484	0.00574	CcSEcCtD
Bosentan—Anxiety—Varenicline—nicotine dependence	0.00483	0.00572	CcSEcCtD
Bosentan—CYP3A4—Xenobiotics—CYP2A7—nicotine dependence	0.00482	0.0309	CbGpPWpGaD
Bosentan—Unspecified disorder of skin and subcutaneous tissue—Varenicline—nicotine dependence	0.00481	0.0057	CcSEcCtD
Bosentan—Discomfort—Varenicline—nicotine dependence	0.00479	0.00567	CcSEcCtD
Bosentan—Dry mouth—Varenicline—nicotine dependence	0.00474	0.00561	CcSEcCtD
Bosentan—Oedema—Varenicline—nicotine dependence	0.00464	0.0055	CcSEcCtD
Bosentan—Infection—Varenicline—nicotine dependence	0.00461	0.00546	CcSEcCtD
Bosentan—Shock—Varenicline—nicotine dependence	0.00457	0.00541	CcSEcCtD
Bosentan—Nervous system disorder—Varenicline—nicotine dependence	0.00455	0.00539	CcSEcCtD
Bosentan—Thrombocytopenia—Varenicline—nicotine dependence	0.00455	0.00539	CcSEcCtD
Bosentan—Tachycardia—Varenicline—nicotine dependence	0.00453	0.00537	CcSEcCtD
Bosentan—Skin disorder—Varenicline—nicotine dependence	0.00451	0.00534	CcSEcCtD
Bosentan—Hyperhidrosis—Varenicline—nicotine dependence	0.00449	0.00532	CcSEcCtD
Bosentan—EDNRA—GPCR ligand binding—TAS2R16—nicotine dependence	0.00444	0.0285	CbGpPWpGaD
Bosentan—Anorexia—Varenicline—nicotine dependence	0.00443	0.00524	CcSEcCtD
Bosentan—Hypotension—Varenicline—nicotine dependence	0.00434	0.00514	CcSEcCtD
Bosentan—Musculoskeletal discomfort—Varenicline—nicotine dependence	0.00423	0.00501	CcSEcCtD
Bosentan—Insomnia—Varenicline—nicotine dependence	0.0042	0.00497	CcSEcCtD
Bosentan—Dyspnoea—Varenicline—nicotine dependence	0.00414	0.0049	CcSEcCtD
Bosentan—Somnolence—Varenicline—nicotine dependence	0.00413	0.00489	CcSEcCtD
Bosentan—Dyspepsia—Varenicline—nicotine dependence	0.00409	0.00484	CcSEcCtD
Bosentan—Decreased appetite—Varenicline—nicotine dependence	0.00404	0.00478	CcSEcCtD
Bosentan—EDNRB—GPCRs, Class A Rhodopsin-like—OPRM1—nicotine dependence	0.00401	0.0257	CbGpPWpGaD
Bosentan—Gastrointestinal disorder—Varenicline—nicotine dependence	0.00401	0.00475	CcSEcCtD
Bosentan—Fatigue—Varenicline—nicotine dependence	0.004	0.00474	CcSEcCtD
Bosentan—Constipation—Varenicline—nicotine dependence	0.00397	0.0047	CcSEcCtD
Bosentan—Pain—Varenicline—nicotine dependence	0.00397	0.0047	CcSEcCtD
Bosentan—Gastrointestinal pain—Varenicline—nicotine dependence	0.0038	0.0045	CcSEcCtD
Bosentan—Urticaria—Varenicline—nicotine dependence	0.00369	0.00437	CcSEcCtD
Bosentan—Body temperature increased—Varenicline—nicotine dependence	0.00367	0.00435	CcSEcCtD
Bosentan—Abdominal pain—Varenicline—nicotine dependence	0.00367	0.00435	CcSEcCtD
Bosentan—EDNRA—Peptide ligand-binding receptors—OPRM1—nicotine dependence	0.00367	0.0235	CbGpPWpGaD
Bosentan—EDNRB—GPCR downstream signaling—TAS2R16—nicotine dependence	0.00351	0.0225	CbGpPWpGaD
Bosentan—EDNRB—Class A/1 (Rhodopsin-like receptors)—OPRM1—nicotine dependence	0.00344	0.0221	CbGpPWpGaD
Bosentan—Hypersensitivity—Varenicline—nicotine dependence	0.00342	0.00405	CcSEcCtD
Bosentan—Asthenia—Varenicline—nicotine dependence	0.00333	0.00395	CcSEcCtD
Bosentan—Pruritus—Varenicline—nicotine dependence	0.00329	0.00389	CcSEcCtD
Bosentan—EDNRB—Signaling by GPCR—TAS2R16—nicotine dependence	0.00319	0.0204	CbGpPWpGaD
Bosentan—Diarrhoea—Varenicline—nicotine dependence	0.00318	0.00376	CcSEcCtD
Bosentan—Dizziness—Varenicline—nicotine dependence	0.00307	0.00364	CcSEcCtD
Bosentan—CYP2C9—Cytochrome P450 - arranged by substrate type—CYP2A7—nicotine dependence	0.00303	0.0195	CbGpPWpGaD
Bosentan—CYP2C9—Oxidation by Cytochrome P450—CYP2A7—nicotine dependence	0.00299	0.0192	CbGpPWpGaD
Bosentan—Vomiting—Varenicline—nicotine dependence	0.00295	0.0035	CcSEcCtD
Bosentan—Rash—Varenicline—nicotine dependence	0.00293	0.00347	CcSEcCtD
Bosentan—Dermatitis—Varenicline—nicotine dependence	0.00293	0.00346	CcSEcCtD
Bosentan—Headache—Varenicline—nicotine dependence	0.00291	0.00345	CcSEcCtD
Bosentan—EDNRB—GPCRs, Class A Rhodopsin-like—DRD2—nicotine dependence	0.0029	0.0186	CbGpPWpGaD
Bosentan—EDNRA—GPCRs, Class A Rhodopsin-like—OPRM1—nicotine dependence	0.00287	0.0184	CbGpPWpGaD
Bosentan—Nausea—Varenicline—nicotine dependence	0.00276	0.00327	CcSEcCtD
Bosentan—EDNRB—GPCR downstream signaling—FGD1—nicotine dependence	0.00275	0.0177	CbGpPWpGaD
Bosentan—EDNRB—GPCR ligand binding—OPRM1—nicotine dependence	0.00262	0.0168	CbGpPWpGaD
Bosentan—EDNRA—GPCR downstream signaling—TAS2R16—nicotine dependence	0.00251	0.0161	CbGpPWpGaD
Bosentan—EDNRB—Signaling by GPCR—FGD1—nicotine dependence	0.0025	0.016	CbGpPWpGaD
Bosentan—EDNRB—Class A/1 (Rhodopsin-like receptors)—DRD2—nicotine dependence	0.00248	0.0159	CbGpPWpGaD
Bosentan—EDNRA—Class A/1 (Rhodopsin-like receptors)—OPRM1—nicotine dependence	0.00246	0.0158	CbGpPWpGaD
Bosentan—CYP2C9—Phase 1 - Functionalization of compounds—CYP2A7—nicotine dependence	0.00246	0.0158	CbGpPWpGaD
Bosentan—EDNRA—Signaling by GPCR—TAS2R16—nicotine dependence	0.00228	0.0146	CbGpPWpGaD
Bosentan—EDNRA—GPCRs, Class A Rhodopsin-like—DRD2—nicotine dependence	0.00208	0.0133	CbGpPWpGaD
Bosentan—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP2A7—nicotine dependence	0.002	0.0128	CbGpPWpGaD
Bosentan—CYP3A4—Oxidation by Cytochrome P450—CYP2A7—nicotine dependence	0.00197	0.0127	CbGpPWpGaD
Bosentan—EDNRA—GPCR downstream signaling—FGD1—nicotine dependence	0.00197	0.0126	CbGpPWpGaD
Bosentan—EDNRB—GPCR ligand binding—DRD2—nicotine dependence	0.00189	0.0121	CbGpPWpGaD
Bosentan—EDNRB—Signaling Pathways—TAS2R16—nicotine dependence	0.00188	0.0121	CbGpPWpGaD
Bosentan—EDNRA—GPCR ligand binding—OPRM1—nicotine dependence	0.00187	0.012	CbGpPWpGaD
Bosentan—EDNRA—Signaling by GPCR—FGD1—nicotine dependence	0.00179	0.0115	CbGpPWpGaD
Bosentan—EDNRA—Class A/1 (Rhodopsin-like receptors)—DRD2—nicotine dependence	0.00178	0.0114	CbGpPWpGaD
Bosentan—CYP3A4—Phase 1 - Functionalization of compounds—CYP2A7—nicotine dependence	0.00162	0.0104	CbGpPWpGaD
Bosentan—EDNRB—GPCR downstream signaling—OPRM1—nicotine dependence	0.00148	0.00949	CbGpPWpGaD
Bosentan—EDNRB—Signaling Pathways—FGD1—nicotine dependence	0.00148	0.00948	CbGpPWpGaD
Bosentan—CYP2C9—Metapathway biotransformation—AKR1B10—nicotine dependence	0.00139	0.00889	CbGpPWpGaD
Bosentan—EDNRA—GPCR ligand binding—DRD2—nicotine dependence	0.00135	0.00869	CbGpPWpGaD
Bosentan—EDNRA—Signaling Pathways—TAS2R16—nicotine dependence	0.00135	0.00865	CbGpPWpGaD
Bosentan—EDNRB—Signaling by GPCR—OPRM1—nicotine dependence	0.00134	0.00862	CbGpPWpGaD
Bosentan—CYP2C9—Biological oxidations—CYP2A7—nicotine dependence	0.00131	0.00838	CbGpPWpGaD
Bosentan—EDNRB—Signaling Pathways—AKR1B10—nicotine dependence	0.0013	0.00837	CbGpPWpGaD
Bosentan—CYP2C9—Metapathway biotransformation—CYP2A7—nicotine dependence	0.00129	0.00827	CbGpPWpGaD
Bosentan—EDNRB—GPCR downstream signaling—DRD2—nicotine dependence	0.00107	0.00686	CbGpPWpGaD
Bosentan—EDNRA—GPCR downstream signaling—OPRM1—nicotine dependence	0.00106	0.00679	CbGpPWpGaD
Bosentan—EDNRA—Signaling Pathways—FGD1—nicotine dependence	0.00106	0.00678	CbGpPWpGaD
Bosentan—EDNRB—Signaling by GPCR—DRD2—nicotine dependence	0.000971	0.00623	CbGpPWpGaD
Bosentan—EDNRA—Signaling by GPCR—OPRM1—nicotine dependence	0.000961	0.00617	CbGpPWpGaD
Bosentan—EDNRA—Signaling Pathways—AKR1B10—nicotine dependence	0.000934	0.00599	CbGpPWpGaD
Bosentan—EDNRB—Signaling Pathways—WASF2—nicotine dependence	0.000919	0.0059	CbGpPWpGaD
Bosentan—CYP3A4—Metapathway biotransformation—AKR1B10—nicotine dependence	0.000914	0.00586	CbGpPWpGaD
Bosentan—EDNRB—Signaling Pathways—WASF1—nicotine dependence	0.000881	0.00566	CbGpPWpGaD
Bosentan—CYP3A4—Biological oxidations—CYP2A7—nicotine dependence	0.000861	0.00553	CbGpPWpGaD
Bosentan—CYP3A4—Metapathway biotransformation—CYP2A7—nicotine dependence	0.00085	0.00545	CbGpPWpGaD
Bosentan—EDNRB—Signaling Pathways—OPRM1—nicotine dependence	0.000793	0.00509	CbGpPWpGaD
Bosentan—EDNRA—GPCR downstream signaling—DRD2—nicotine dependence	0.000765	0.00491	CbGpPWpGaD
Bosentan—EDNRA—Signaling by GPCR—DRD2—nicotine dependence	0.000695	0.00446	CbGpPWpGaD
Bosentan—ABCB11—Metabolism—CYP2A7—nicotine dependence	0.000669	0.00429	CbGpPWpGaD
Bosentan—EDNRA—Signaling Pathways—WASF2—nicotine dependence	0.000658	0.00422	CbGpPWpGaD
Bosentan—EDNRA—Signaling Pathways—WASF1—nicotine dependence	0.000631	0.00405	CbGpPWpGaD
Bosentan—EDNRB—Signaling Pathways—DRD2—nicotine dependence	0.000574	0.00368	CbGpPWpGaD
Bosentan—EDNRA—Signaling Pathways—OPRM1—nicotine dependence	0.000568	0.00364	CbGpPWpGaD
Bosentan—EDNRA—Signaling Pathways—DRD2—nicotine dependence	0.000411	0.00264	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism—CYP2A7—nicotine dependence	0.000223	0.00143	CbGpPWpGaD
Bosentan—CYP3A4—Metabolism—CYP2A7—nicotine dependence	0.000147	0.000945	CbGpPWpGaD
